- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00172224
Dynamic Magnetic Resonance (MR) Study in Evaluating the Vertebral Bone Marrow Perfusion and Its Related Research
Dynamic MR Study in Evaluating the Vertebral Bone Marrow Perfusion and Its Related Research
The etiology and pathogenesis of osteoporosis has been extensively discussed. The relationship between bone blood circulation and the formation of bony trabeculae has been less understood. There is plenty of indirect evidence highly suggestive of the correlation between these two factors, such as: the number of blood vessels in the per unit area of the bone marrow was decreased in the osteoporotic bone, indicating the possible role of a microvascular defect in the pathogenesis of osteoporosis.
Furthermore, the bone mineral density in severe arteriosclerotic patients was lower than in the less affected subjects. In a large scale epidemiologic study, diminished bone mineral density was strongly associated with increased deaths from stroke. Osteopenia was also associated with an increased risk of stroke. These reports highly suggest the effect of ischemia on bone metabolism and make the investigators more interested in further investigation.
A dynamic contrast-enhanced magnetic resonance (MR) study was used recently in evaluating the blood perfusion of bone tumors. This method also has a strong correlation with the microsphere blood flow measurements. The investigator (T.F. Shih) used the dynamic MR in her recent two researches:
- To differentiate benign versus malignant spinal compression fractures.
- To evaluate the blood perfusion of non-fractured, normal-appearing vertebral bodies and find its significant correlation with aging and sex.
The alterations of bone marrow perfusion are synchronous with the changes of bone mineral density. Thus, based on the investigators' previous research work, they propose to further explore the relationship between bone marrow perfusion and bone mineral density in different age groups.
Study Overview
Status
Conditions
Detailed Description
The etiology and pathogenesis of osteoporosis has been extensively discussed. The relationship between bone blood circulation and the formation of bony trabeculae has been less understood. There is plenty of indirect evidence highly suggestive of the correlation between these two factors, such as: the number of blood vessels in the per unit area of the bone marrow was decreased in the osteoporotic bone, indicating the possible role of a microvascular defect in the pathogenesis of osteoporosis.
Furthermore, the bone mineral density in severe arteriosclerotic patients was lower than in the less affected subjects. In a large scale epidemiologic study, diminished bone mineral density was strongly associated with increased deaths from stroke. Osteopenia was also associated with an increased risk of stroke. These reports highly suggest the effect of ischemia on bone metabolism and make the investigators more interested in further investigation.
A dynamic contrast-enhanced magnetic resonance (MR) study was used recently in evaluating the blood perfusion of bone tumors. This method also has a strong correlation with the microsphere blood flow measurements. The investigator (T.F. Shih) used the dynamic MR in her recent two researches:
- To differentiate benign versus malignant spinal compression fractures.
- To evaluate the blood perfusion of non-fractured, normal-appearing vertebral bodies and find its significant correlation with aging and sex.
The alterations of bone marrow perfusion are synchronous with the changes of bone mineral density. Thus, based on the investigators' previous research work, they propose to further explore the relationship between bone marrow perfusion and bone mineral density in different age groups.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan
- Tiffany Ting-Fang Shih
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Normal subjects
- Elder subjects with osteoporosis
Exclusion Criteria:
- History of malignancy or infection
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
osteoporosis
|
Collaborators and Investigators
Investigators
- Principal Investigator: Tiffany Ting-Fang Shih, M.D., Department of Medical Image, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 32244
- NSC 91-2314-B-002-395
- NSC 92-2314-B-002-172
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States, Puerto Rico
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPost Menopausal OsteoporosisFrance
-
AmgenCompletedPost Menopausal OsteoporosisFrance
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisSpain, South Africa, Germany, Mexico, United States, Canada, France, United Kingdom, Italy, Belgium, Australia, Poland, Denmark, Hungary, Czech Republic, Norway
-
Hoffmann-La RocheGlaxoSmithKlineCompletedPost Menopausal OsteoporosisFrance
-
Novartis PharmaceuticalsCompletedPost-menopausal OsteoporosisColombia, Belgium, Sweden, Hong Kong, United States, Hungary, Switzerland, Australia, Germany, Italy, Canada, Poland, Argentina, Thailand, Norway, New Zealand, France, Finland